COLLEGIUM PHARMACEUTICAL, INC Quarterly Amortization of Intangible Assets in USD from Q2 2016 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
Summary
Collegium Pharmaceutical, Inc quarterly/annual Amortization of Intangible Assets history and growth rate from Q2 2016 to Q2 2024.
  • Collegium Pharmaceutical, Inc Amortization of Intangible Assets for the quarter ending June 30, 2024 was $34.5M, a 7.87% decline year-over-year.
  • Collegium Pharmaceutical, Inc annual Amortization of Intangible Assets for 2021 was $67.2M, a 10.7% increase from 2020.
  • Collegium Pharmaceutical, Inc annual Amortization of Intangible Assets for 2020 was $60.7M, a 311% increase from 2019.
  • Collegium Pharmaceutical, Inc annual Amortization of Intangible Assets for 2019 was $14.8M, a 86.6% decline from 2018.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $34.5M -$2.95M -7.87% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $34.5M -$2.95M -7.87% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q3 2023 $36.3M -$1.24M -3.29% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $37.5M -$38K -0.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $37.5M +$18.5M +98% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q3 2022 $111M $37.6M +$20.8M +124% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $90M $37.5M +$20.7M +123% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $69.3M $18.9M +$2.13M +12.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $67.2M $16.8M $0 0% Oct 1, 2021 Dec 31, 2021 10-K 2022-02-24
Q3 2021 $67.2M $16.8M +$1K +0.01% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $67.2M $16.8M $0 0% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $67.2M $16.8M +$6.5M +63.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $60.7M $16.8M +$13.1M +355% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-24
Q3 2020 $47.6M $16.8M +$13.1M +355% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-24
Q2 2020 $34.5M $16.8M +$13.1M +355% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-24
Q1 2020 $21.4M $10.3M +$6.61M +179% Jan 1, 2020 Mar 31, 2020 10-K 2022-02-24
Q4 2019 $14.8M $3.69M -$11.8M -76.2% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 $26.6M $3.69M -$28.7M -88.6% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 $55.3M $3.69M -$28.7M -88.6% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 $84M $3.69M -$25.8M -87.5% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 $110M $15.5M +$15.5M +46852% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $94.4M $32.4M +$32.4M +67415% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $62M $32.4M +$32.4M +68851% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $29.7M $29.5M +$29.4M +22612% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $258K $33K Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 $48K -$179K -78.9% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $47K +$47K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 $130K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q3 2016 $227K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 $0 Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.